Suchergebnisse - "Lucassen, Wim"

PubPharm (78)

21

CHARGE-AF in a national routine primary care electronic health records database in the Netherlands : validation for 5-year risk of atrial fibrillation and implications for patient selection in atrial fibrillation screening

enthalten in: Open heart | 2021

von Himmelreich, J. | Lucassen, W. | Harskamp, R. | +3

ErratumIn: Open Heart. 2021 Oct;8(2):1. - PMID 34663753

22

Opportunistic screening versus usual care for detection of atrial fibrillation in primary care : cluster randomised controlled trial

enthalten in: BMJ (Clinical research ed.) | 2020

von Uittenbogaart, S. | Verbiest-van Gurp, N. | Lucassen, W. | +6

23

Wel of niet behandelen op geleide van B-type natriuretisch peptide

enthalten in: Huisarts en wetenschap | 2020

von Lucassen, W. | van Weert, H.

24

Wel of niet behandelen op geleide van B-type natriuretisch peptide

enthalten in: Huisarts en wetenschap | 2020

von Lucassen, W. | van Weert, H.

25

Wel of niet behandelen op geleide van B-type natriuretisch peptide

enthalten in: Huisarts en wetenschap | 2020

von Lucassen, W. | van Weert, H.

26

Rationale and design of a cohort study evaluating triage of acute chest pain in out-of-hours primary care in the Netherlands (TRACE)

enthalten in: Primary health care research & development | 2020

von Manten, A. | Cuijpers, C. | Rietveld, R. | +7

27

Prediction models for atrial fibrillation applicable in the community : a systematic review and meta-analysis

enthalten in: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology | 2020

von Himmelreich, J. | Veelers, L. | Lucassen, W. | +4

28

Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation

enthalten in: Cardiovascular drugs and therapy | 2019

von Harskamp, R. | Teichert, M. | Lucassen, W. | +2

29

Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation

enthalten in: Cardiovascular drugs and therapy | 2019

von Harskamp, R. | Teichert, M. | Lucassen, W. | +2

30

Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation

enthalten in: Cardiovascular drugs and therapy | 2019

von Harskamp, R. | Teichert, M. | Lucassen, W. | +2